RIL
VKTX icon

Rothschild Investment LLC’s Viking Therapeutics VKTX Stock Holding History

Rothschild Investment LLC’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$260 Buy
8
+7
+700% +$225 ﹤0.01% 3256
2025
Q4 		$35 Buy
+1
New +$35 ﹤0.01% 3301
2024
Q3 		– Sell
-30
Closed -$1.59K – 2985
2024
Q2 		$1.59K Buy
30
+20
+200% +$1.31K ﹤0.01% 1473
2024
Q1 		$820 Buy
+10
New +$445 ﹤0.01% 1276

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Rothschild Investment LLC's VKTX Position: Q1 2026 in Review

Rothschild Investment LLC increased its Viking Therapeutics (VKTX) stake by 700% in Q1 2026, buying an estimated $225 and bringing the position to 8 shares worth $260. The position accounts for ﹤0.01% of the portfolio, ranked #3256.

Rothschild Investment LLC first reported a position in VKTX in Q1 2024 and has held it in 4 quarters since. The position peaked at $1.59K in Q2 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Rothschild Investment LLC held 8 shares of Viking Therapeutics worth $260 as of Q1 2026.
  • Rothschild Investment LLC bought 7 Viking Therapeutics shares in Q1 2026, an estimated $225.
  • Viking Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q1 2026, its #3256 holding.
  • Rothschild Investment LLC first reported a position in Viking Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • Rothschild Investment LLC's Viking Therapeutics position peaked at $1.59K in Q2 2024.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Rothschild Investment LLC's 13F filing for Q1 2026, filed 7 May 2026.